Sivridaş, M.; Creemers, R.H.; Wong, D.R.; Boekema, P.J.; Römkens, T.E.H.; Gilissen, L.P.L.; van Bodegraven, A.A.; Loeff, F.C.; Rispens, T.; Derijks, L.J.J.
Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment—TUMMY Study. Pharmaceutics 2023, 15, 972.
https://doi.org/10.3390/pharmaceutics15030972
AMA Style
Sivridaş M, Creemers RH, Wong DR, Boekema PJ, Römkens TEH, Gilissen LPL, van Bodegraven AA, Loeff FC, Rispens T, Derijks LJJ.
Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment—TUMMY Study. Pharmaceutics. 2023; 15(3):972.
https://doi.org/10.3390/pharmaceutics15030972
Chicago/Turabian Style
Sivridaş, Merve, Rob H. Creemers, Dennis R. Wong, Paul J. Boekema, Tessa E. H. Römkens, Lennard P. L. Gilissen, Adriaan A. van Bodegraven, Floris C. Loeff, Theo Rispens, and Luc J. J. Derijks.
2023. "Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment—TUMMY Study" Pharmaceutics 15, no. 3: 972.
https://doi.org/10.3390/pharmaceutics15030972
APA Style
Sivridaş, M., Creemers, R. H., Wong, D. R., Boekema, P. J., Römkens, T. E. H., Gilissen, L. P. L., van Bodegraven, A. A., Loeff, F. C., Rispens, T., & Derijks, L. J. J.
(2023). Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment—TUMMY Study. Pharmaceutics, 15(3), 972.
https://doi.org/10.3390/pharmaceutics15030972